Ultrasound-Guided Subtransverse Interligamentary Block Versus Thoracic Paravertebral Block for Postoperative Analgesia in Patients Undergoing Open Nephrectomy

NCT ID: NCT07138794

Last Updated: 2025-08-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-23

Study Completion Date

2026-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to compare ultrasound-guided subtransverse process interligamentary (STIL) block versus thoracic paravertebral block (TPVB) for postoperative analgesia in patients undergoing open nephrectomy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acute pain physiopathology is explained as it is mediated by inflammatory cell infiltration, activation of spinal cord pain pathways, and also by reflexive muscle spasm. All of these three mechanisms of acute pain are typically ameliorated during the postoperative recovery.

A thoracic paravertebral block (TPVB) shows comparable analgesic efficacy with fewer side effects compared with thoracic epidural analgesia in patients undergoing thoracotomy.

The recently introduced subtransverse process interligamentary (STIL) block offers a safer alternative by targeting thoracic nerves without entering paravertebral space.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subtransverse Interligamentary Block Thoracic Paravertebral Block Postoperative Analgesia Open Nephrectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

STIL group

Patients will receive subtransverse process interligamentary (STIL) block using 20ml of bupivacaine 0.25%.

Group Type EXPERIMENTAL

Subtransverse process interligamentary

Intervention Type OTHER

Patients will receive subtransverse process interligamentary (STIL) block using 20ml of bupivacaine 0.25%.

TPVB group

Patients will receive a thoracic paravertebral block (TPVB) using 20ml of bupivacaine 0.25%.

Group Type EXPERIMENTAL

Thoracic paravertebral block

Intervention Type OTHER

Patients will receive a thoracic paravertebral block (TPVB) using 20ml of bupivacaine 0.25%.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Subtransverse process interligamentary

Patients will receive subtransverse process interligamentary (STIL) block using 20ml of bupivacaine 0.25%.

Intervention Type OTHER

Thoracic paravertebral block

Patients will receive a thoracic paravertebral block (TPVB) using 20ml of bupivacaine 0.25%.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 18 to 65 years.
* Both sexes.
* American Society of Anesthesiology (ASA) physical status I-III.
* Undergoing open nephrectomy under general anesthesia.

Exclusion Criteria

* History of allergies to local anesthetics.
* Opioid dependency.
* Bleeding or coagulation disorders.
* Psychiatric and neurological disorder.
* Local infection at the site of injection.
* Body mass index (BMI) \> 35 kg/m2.
* Severe heart, lung, liver, and renal dysfunction.
* Pregnant or lactating women.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tanta University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohammed Said ElSharkawy

Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tanta University

Tanta, El-Gharbia, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mohammed S ElSharkawy, MD

Role: CONTACT

00201148207870

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mohammed S Elsharkawy, MD

Role: primary

00201148207870

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

36264PR1283/7/25

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.